P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA‐CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON‐CELLULAR ANTI‐B‐CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY

Saved in:
Bibliographic Details
Published inHemaSphere Vol. 7; no. S2; pp. 25 - 26
Main Authors Donk, N., Mateos, M.‐V., Cohen, Y.C., Rodriguez‐Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San‐Miguel, J.
Format Journal Article
LanguageEnglish
Published Philadelphia, PA Lippincott Williams & Wilkins 09.05.2023
Wiley
Online AccessGet full text

Cover

More Information
ISSN:2572-9241
2572-9241
DOI:10.1097/01.HS9.0000936240.43628.7e